CAJ | 학술논문

由于老年患者本身的特点及疾病的生物学特征,老年急性髓系白血病(AML)患者的疗效及预后均较差.近年老年AML患者的治疗取得许多进展诸如标准化疗方案的改良、新化疗药物的应用、免疫治疗、表观遗传学治疗药物及靶向治疗药物的研发等,临床试验结果提示部分患者疗效改善.
유우노년환자본신적특점급질병적생물학특정,노년급성수계백혈병(AML)환자적료효급예후균교차.근년노년AML환자적치료취득허다진전제여표준화료방안적개량、신화료약물적응용、면역치료、표관유전학치료약물급파향치료약물적연발등,림상시험결과제시부분환자료효개선.
Acute myeloid leukemias (AML) in elderly patients showed less well response to therapy as well as relative poor prognosis, due to features of both host and disease biology in the elder. During the past decade, treatments for elderly AML have yielded some advances, including improvements in conventional chemotherapy, application of novel chemotherapeutic agents, immunotherapy approaches, and investigation of epigenetic drugs and targeted therapies, to which some subgroups in clinical trials have showed better response. These advances in current treatments of elderly AML will be reviewed.